Drug Profile
Netazepide - Trio Medicines
Alternative Names: sograzepide; YF 476Latest Information Update: 29 Nov 2022
Price :
$50
*
At a glance
- Originator Astellas Pharma; Trio Medicines
- Developer Ferring Pharmaceuticals; Trio Medicines
- Class Antibacterials; Antineoplastics; Antiulcers; Benzodiazepines; Phenylurea compounds; Pyridines; Small molecules
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Barrett's oesophagus; Neuroendocrine tumours
- Discontinued Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Reflux oesophagitis
Most Recent Events
- 29 Nov 2022 Netazepide is still in phase-II trials for Neuroendocrine tumours in USA (Trio Medicines pipeline, November 2022)
- 03 Aug 2020 Discontinued - Phase-II for Helicobacter infections in United Kingdom (PO) (TRIO Medicines pipeline, August 2020)
- 14 Aug 2019 Trio Medicines terminates a phase II trial due to poor recruitment in Neuroendocrine tumours (Gastric carcinoids) in USA (PO) (NCT02454075)